PEG-MGF
Pegylated Mechano Growth Factor
ANECDOTAL · PEGYLATED IGF-1 SPLICE VARIANT; ANABOLIC
▓ 1 indexed citations across EuropePMC (1).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Mechanism of action
PEG conjugation extends half-life of MGF for systemic action
Researched effects
Systemic muscle repair signaling; longer action vs MGF
Live evidence
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
200-400 mcg SC 1-2x weekly
Known concerns
Immunogenicity concerns with PEG; limited safety data
Top-ranked picks
1 pre-curated authoritative sources, ranked by journal tier and study weight.
Full citation library
Year distribution
No references match — clear filters.
Research Articles
1-
1.
Neurodegeneration is characterized by progressive loss of structure and function of neurons. Several therapeutic methods and drugs are available to alleviate the symptoms of these diseases. The currently used delivery strategies such as implantation of catheters, intracarotid infusions, surgeries, and chemotherapies are invasive in nature and pose a greater risk of postsurgical complications, which can have fatal side effects. The current study utilizes a peptide (TAT and MGF) tagged PEGylated c…
Curated sources on file
2- 1.
-
2.
Note: PEG-MGF differs from MGF only in pegylation for extended half-life; no independent indexed primary literature exists. Cited paper describes the parent MGF peptide.